A carregar...
Switching from sildenafil to riociguat for the treatment of PAH and inoperable CTEPH: Real-life experiences
Riociguat is a novel soluble guanylate cyclase stimulator that is approved for the treatment of patients with pulmonary arterial hypertension (PAH) and patients with inoperable chronic thromboembolic pulmonary hypertension (CTEPH) or persistent/recurrent CTEPH after pulmonary endarterectomy (PEA). A...
Na minha lista:
| Publicado no: | Respir Med Case Rep |
|---|---|
| Main Authors: | , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Elsevier
2017
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5476463/ https://ncbi.nlm.nih.gov/pubmed/28652963 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.rmcr.2017.06.005 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|